EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Glucagon-Like Peptide 1 Receptor Agonists and Age-Related Macular Degeneration Incidence

Shahin Hallaj, Takashi Nishida, Alireza Kamalipour, Christopher A Longhurst, William R Freeman, Sally L Baxter, Aaron Boussina

Ophthalmology Retina · 2026-10 · 10 (10) · 1017-1026

DOI: 10.1016/j.oret.2026.05.016 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Ophthalmology Retina, 2026-10. Verfasst von Shahin Hallaj und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Ophthalmology Informatics and Data Science, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Macular Degeneration, Wet Macular Degeneration. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NEI NIH HHS, Research to Prevent Blindness.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate the association between glucagon-like peptide-1 receptor agonist (GLP-1RA) use and the incidence of age-related macular degeneration (AMD) and neovascular AMD (nAMD) among adults with diabetes. DESIGN: Retrospective, propensity score-matched cohort study. PARTICIPANTS: Adults with diabetes who initiated a GLP-1RA or another noninsulin antidiabetic agent. In Epic Cosmos, 2 797 686 GLP-1RA users were matched 1:1 to 2 797 686 active comparators. METHODS: We analyzed de-identified electronic health record data from Epic Cosmos and independently replicated the primary analyses in the University of California Health Data Warehouse. Individuals with prevalent AMD or nAMD and those with prior anti-VEGF treatment were excluded. One-to-one nearest-neighbor propensity score matching balanced demographics, diabetes duration, comorbidities, smoking, diabetic retinopathy, obesity, and eye-care utilization. Cumulative incidence at 1, 5, and 10 years was estimated using Kaplan-Meier methods, and adjusted associations were evaluated using multivariable Cox proportional hazards models. MAIN OUTCOME MEASURES: Incidence of any AMD and nAMD. RESULTS: In the matched Epic Cosmos cohort (total N = 5 595 372), GLP-1RA use was associated with lower cumulative incidence of any AMD at 1 year (0.187% [95% confidence interval {CI}, 0.182%-0.192%] vs. 0.294% [95% CI, 0.287%-0.301%]), 5 years (0.924% [95% CI, 0.907%-0.941%] vs. 1.278% [95% CI, 1.260%-1.296%]), and 10 years (5.561% [95% CI, 4.719%-6.549%] vs. 6.540% [95% CI, 6.017%-7.108%]); all P < 0.001. Unadjusted cumulative incidence of nAMD was also lower among GLP-1RA users at 1 year (0.047% vs. 0.065%), 5 years (0.280% vs. 0.340%), and 10 years (1.874% vs. 2.393%); all P < 0.001. In multivariable Cox models, GLP-1RA use was independently associated with lower hazard of any AMD (hazard ratio [HR], 0.84; 95% CI, 0.83-0.86; P < 0.001) and was not associated with an increased hazard of nAMD (HR, 1.00; 95% CI, 0.97-1.04; P = 0.79). In the independent University of California Health Data Warehouse cohort, GLP-1RA use was likewise associated with lower AMD incidence at 5 and 10 years, whereas nAMD incidence did not differ significantly between groups. CONCLUSIONS: Among adults with diabetes, GLP-1RA use was associated with lower incident AMD and was not associated with increased nAMD risk. These findings provide reassurance regarding ocular safety and support a potential protective association for earlier AMD phenotypes. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsMacular DegenerationWet Macular DegenerationAgedFemaleHumansMaleMiddle AgedFollow-Up StudiesHypoglycemic AgentsIncidenceRetrospective StudiesRisk Factors

Stichwörter der Autor:innen

Age-related macular degenerationGlucagon-like peptide-1 receptor agonistsNeovascular.

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Division of Ophthalmology Informatics and Data Science, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, San Diego, California; Viterbi Family Department of Ophtha…
  • Viterbi Family Department of Ophthalmology, Hamilton Glaucoma Center, Shiley Eye Institute, University of California San Diego, San Diego, California.
  • Division of Biomedical Informatics, Department of Medicine, University of California San Diego, San Diego, California; Division of Biomedical Informatics, Department of Medicine, Joan & Irwin Jacobs Center for Health In…
  • Viterbi Family Department of Ophthalmology, Jacobs Retina Center, Shiley Eye Institute, University of California San Diego, San Diego, California.

Förderung

  • NIH HHS
  • NEI NIH HHS
  • Research to Prevent Blindness
  • National Institutes of Health

Zitieren

APA

Hallaj, S., Nishida, T., Kamalipour, A., Longhurst, C. A., Freeman, W. R., Baxter, S. L., & Boussina, A. (2026). Glucagon-Like Peptide 1 Receptor Agonists and Age-Related Macular Degeneration Incidence. Ophthalmology Retina, 10(10), 1017-1026. https://doi.org/10.1016/j.oret.2026.05.016

Vancouver

Hallaj S, Nishida T, Kamalipour A, Longhurst CA, Freeman WR, Baxter SL, et al. Glucagon-Like Peptide 1 Receptor Agonists and Age-Related Macular Degeneration Incidence. Ophthalmology Retina. 2026;10(10):1017-1026. doi:10.1016/j.oret.2026.05.016

BibTeX
@article{Hallaj2026,
  author = {Hallaj, Shahin and Nishida, Takashi and Kamalipour, Alireza and Longhurst, Christopher A and Freeman, William R and Baxter, Sally L and Boussina, Aaron},
  title = {Glucagon-Like Peptide 1 Receptor Agonists and Age-Related Macular Degeneration Incidence},
  journal = {Ophthalmology Retina},
  year = {2026},
  volume = {10},
  number = {10},
  pages = {1017--1026},
  doi = {10.1016/j.oret.2026.05.016}
}
Kostenlos starten →